Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) filed Quarterly Report for the period ended 2009-03-31.
Questcor Pharmaceuticals Inc. formerly Cypros Pharmaceutical Corporationis an integrated specialty pharmaceutical company focused on the development acquisition and marketing of innovative acute care and critical care hospital/specialty pharmaceutical products. Questcor Pharmaceuticals Inc. has a market cap of $308.2 million; its shares were traded at around $4.69 with a P/E ratio of 8.9 and P/S ratio of 3.2.
Highlight of Business Operations:The Company utilizes the services of CuraScript, Inc. which has a specialty distributor subsidiary, CuraScript Specialty Distribution, Inc. (CuraScript SD) and a group of specialty pharmacies (CuraScript SP). During July 2007, the Company began utilizing CuraScript SD to store and distribute Acthar. Effective August 1, 2007, the Company no longer sells Acthar to wholesalers and all of the Companys proceeds from sales of Acthar in the United States are received from CuraScript SD. The Company sells Acthar to CuraScript SD at a discount from the Companys list price. CuraScript SD sells Acthar primarily to hospitals and specialty pharmacies. Product sales are recognized net of this discount upon receipt of the product by CuraScript SD. In April 2008, the Company announced the amendment of its distribution agreement with CuraScript SD, which became effective on June 1, 2008. Under the new terms, the discount provided by the Company to CuraScript SD is reduced from $1,047 per vial to $230 per vial. The new discounted sales price to CuraScript SD is $23,039 per vial and the stated list price remains at $23,269. However, under the new terms the pricing to CuraScript SD customers is unchanged. The amount of the discount to CuraScript SD is subject to annual adjustments based on the Consumer Price Index. In addition, the payment terms have been reduced from 60 days to 30 days from when product is received by CuraScript SD. Under the Companys distribution agreement with CuraScript SD, if the price of Acthar is reduced, CuraScript SD will receive a shelf-stock adjustment credit based upon the amount of product in their inventory at the time of the price reduction. Any reduction in the selling price of Acthar is at the Companys discretion. To date, there have been no such price reductions. The Company sells Doral to wholesalers, who in turn sell Doral primarily to retail pharmacies and hospitals. The Company does not require collateral from its customers.
Read the The complete Report